|
|
Article: NitroMed, Inc. Reports Financial Results for First Quarter 2005; Conference Call May 5 at 5:00 PM EDT.
- Article from:
- Business Wire
- Article date:
- May 5, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LEXINGTON, Mass. -- NitroMed, Inc. (NASDAQ: NTMD), today reported financial results for the first quarter ended March 31, 2005.
Total revenue for the quarter ended March 31, 2005 was $0.4 million which consisted of license revenue. This compared to $2.3 million for the same period in 2004. The decrease in revenue in the 2005 period is attributable to the termination of our development agreement with Merck in November 2004.
Research and development expense for the quarter ended March 31, 2005 was $7.7 million compared to $5.6 million for the same period in 2004. The increase in research and development expenses was primarily due to increased medical ...
Related newspaper, magazine, and journal articles:
|
|
Article: NitroMed Announces Sale of Common Stock.
Business Wire;
May 24, 2007 ;
700+ words
... ... jurisdiction. About NitroMed, Inc. NitroMed of Lexington, Massachusetts ... clinical trial and is marketed by NitroMed through a specialty medicines ... a registered trademark of NitroMed, Inc. Forward Looking Statements ... strategic partners related to its product candidate portfolio on ...
|
|